Americas to Have Lion’s Share in Diabetic Retinopathy Market
Market Analysis:
The global Diabetic
Retinopathy Market is anticipated to grow at a 11.9% CAGR between
2019-2025, reveals the new Market Research Future (MRFR) report.
Diabetic retinopathy, simply put, is a diabetes complication that affects the
eyes. It is of two types- proliferative (advanced stage) and non-proliferative
(milder form).
Various factors are propelling
the diabetic retinopathy market growth. Such factors, as per the latest Market
Research Future report, include the advancement of patient monitoring, growing
awareness about diabetic retinopathy treatment, rising disposable income,
increased health awareness, changing lifestyle, and rise in diabetes patients
worldwide. Additional factors pushing diabetic retinopathy market growth
include an increase in the geriatric population and an increasing prevalence of
blindness owing to diabetes.
On the flip side, lack of
insurance facilities, extended time of approval for drugs, and shortage of
skilled ophthalmologists are factors that may restrict the diabetic retinopathy
market growth during the forecast period.
Key Players:
·
BCN Peptides
·
Kowa Group
·
Ampio Pharmaceuticals
·
Glycadia Pharmaceuticals
·
Alimera Sciences
·
Genentech
·
Sirnaomics
·
Actavis Plc
·
ThromboGenics
·
Regeneron Pharmaceuticals Inc
·
Bayer
·
Novartis AG
Market Segmentation:
·
The Global Diabetic Retinopathy Market
has been segmented based on type, treatment, end-user, and region.
·
The diabetic retinopathy market, based on
type, has been segmented into non-proliferative and proliferative.
·
The diabetic retinopathy market, based on
treatment, has been segmented into anti-VEGF drugs, laser photocoagulation,
vitreoretinal surgery, and steroid injection.
·
The diabetic retinopathy market, based on
end-user, has been segmented into hospitals, ambulatory surgical centers, and
others.
Regional Analysis:
By region, the diabetic
retinopathy market report covers the latest trends and growth opportunities
across the Americas, the Asia Pacific, the Middle East and Africa, and Europe.
Of these, the Americas is projected to have the lion’s share in the market
during the forecast period. Factors pushing the growth of the diabetic
retinopathy market in the region include growing focus on preventive care for
different chronic diseases, especially obesity and diabetes, presence of
notable players in the region, availability of diagnostic & treatment
services, and rising number of specialty care centers. The US is the prime
contributor in the region.
The diabetic retinopathy
market in Europe will have the second-largest share in the market during the
forecast period. Factors pushing the growth of the diabetic retinopathy market
in the region include on-going research activities, early diagnosis, focus on
constant health monitoring, and rising prevalence of diabetes.
Comments
Post a Comment